The Editor's Roundtable: Revisiting the Role of Beta Blockers in Hypertension

American Journal of Cardiology

Volumn 100, Issue 2, 2007, Pages 253-267

  Roberts, William C ^a   Black, Henry R ^b   Bakris, George L ^c   Mason, R Preston ^d   Giles, Thomas D ^e   Sulkes, Destry J ^f  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Medsite Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CALCIUM ANTAGONIST; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LABETALOL; LISINOPRIL; LOSARTAN; METOPROLOL; MEVINOLIN; NADOLOL; NEBIVOLOL; NITRIC OXIDE; PLACEBO; PRAZOSIN; PROPRANOLOL; TIMOLOL; UNCLASSIFIED DRUG; VERAPAMIL; VERELAN PM;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE MONITORING; BRADYCARDIA; BRONCHOSPASM; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG USE; EARLY DIAGNOSIS; FATIGUE; HEADACHE; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSOMNIA; LIFESTYLE; PATHOPHYSIOLOGY; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK FACTOR; SALT INTAKE; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34447328110     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.03.032     Document Type: Note

References (74)

1. Joint National Committee on Detection, Evaluation, and Treatment of High BP. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High BP (JNC V). Arch Intern Med 153 (1993) 154-183
2. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 304 (1992) 405-412
3. Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caufield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., Ostergren J., and ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-BP Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
4. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H., and LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
5. Lindholm L.H., Carlberg B., and Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension?. A meta-analysis. Lancet 366 (2005) 1545-1553
6. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., Roccela E.J., and National High BP Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High BP. The JNC 7 report. JAMA 289 (2003) 2560-2572
7. Rosamond W., Flegal K., Friday G., Furie K., Go A., Greenlund K., Haase N., Ho M., Howard V., Kissela B., Kittner S., Lloyd-Jones D., McDermott M., Meigs J., Moy C., Nichol G., O'Donnell C.J., Roger V., Rumsfeld J., Sorlie P., Steinberger J., Thom T., Wasserthiel-Smoller S., Hong Y., and American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
8. Hertz R.P., Unger A.N., Cornell J.A., and Saunders E. Racial disparities in hypertension prevalence, awareness, and management. Arch Intern Med 165 (2005) 2098-2104
9. Kannel W.B. Role of BP in cardiovascular disease: the Framingham Study. Angiology 26 (1975) 1-14
10. Multiple Risk Factor Intervention Trial (MRFIT) Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Prev Med 15 (1986) 254-273
11. Psaty B.M., Smith N.L., Siscovick D.S., Koepsell T.D., Weiss N.S., Heckbert S.R., Lemaitre R.N., Wagner E.H., and Furberg C.D. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 277 (1997) 739-745
12. Neal B., MacMahon S., Chapman N., and BP Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overview of randomised trials. Lancet 356 (2000) 1955-1964
13. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., and Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular mortality: a meta analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
14. López-Séndon J., Swedberg K., McMurray J., Tamargo J., Maggioni A.P., Dargie H., Tendera M., Waagstein F., Kjekshus J., Lechat P., and Torp-Pedersen C. Expert consensus document on β-adrenergic receptor blockers. The Task Force on β-Blockers of the European Society of Cardiology. Eur Heart J 25 (2004) 1341-1362
15. Struyker-Boudier H.A., and Smits J.F. Antihypertensive action of β-adrenoceptor blocking drugs. The role of intrarenal mechanisms. Am J Hypertens 2 (1989) 237S-240S
16. Pepine C.J., Cohn P.F., Deedwania P.C., Gibson R.S., Handberg E., Hill J.A., Miller E., Marks R.G., and Thadani U. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 90 (1994) 762-768
17. von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J Am Coll Cardiol 25 (1995) 231-238
18. Fox K.M., Mulcahy D., Findlay I., Ford I., and Dargie H.J. The Total Ischemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and total ischaemic burden in 608 patients with stable angina. Eur Heart J 17 (1996) 96-103
19. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2017
20. CIBIS-II Study Group. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
21. Packer M., Fowler M.B., Roecker E.B., Coats A.J., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Staiger C., Holcslaw T.L., Amann-Zalan I., DeMets D.L., and Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 (2002) 2194-2199
22. Bonet S., Agusti A., Arnau J.M., Vidal X., Diogene E., Galve E., and Laporte J.R. β-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med 160 (2000) 621-627
23. Castellano M., and Bohm M. The cardiac β-adrenoreceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Hypertension 29 (1997) 715-722
24. β-Blocker Heart Attack Study Group. The β-blocker heart attack trial. JAMA 246 (1981) 2073-2074
25. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304 (1981) 801-807
26. Freemantle N., Cleland J., Young P., Mason J., and Harrison J. β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318 (1999) 1730-1737
27. Rizzon P., Di Biase M., Chiddo A., Mastrangelo D., and Sorgente L. Electrophysiological properties of intravenous metoprolol in man. Br Heart J 40 (1978) 650-655
28. Ellison K.E., and Gandhi G. Optimising the use of β-adrenoceptor antagonists in coronary artery disease. Drugs 65 (2005) 787-797
29. Tafreshi M.J., and Weinacker A.B. β-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma. Pharmacotherapy 19 (1999) 974-978
30. Everly M.J., Heaton P.C., and Cluxton Jr. R.J. β-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother 38 (2004) 286-293
31. Dornhorst A., Powell S.H., and Pensky J. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. Lancet 1 (1985) 123-126
32. Jacob S., Rett K., and Henriksen E.J. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of β-blocking agents?. Am J Hypertens 11 (1998) 1258-1265
33. Giugliano D., Acampora R., Marfella R., De Rosa N., Ziccardi P., Ragone R., De Angelis L., and D'Onofrio F. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 126 (1997) 955-959
34. Bakris G.L., Fonseca V., Katholi R.E., McGill J.B., Messerli F.H., Phillips R.A., Raskin P., Wright Jr. J.T., Oakes R., Lukas M.A., Anderson K.M., Bell D.S., and GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292 (2004) 2227-2236
35. Sarafidis P.A., and Bakris G.L. Antihypertensive treatment with β-blockers and the spectrum of glycaemic control. QMJ 99 (2006) 431-436
36. Kolendorf K., Jensen H.A., Holst J.J., and Poulsen J.E. Effect of acute selective β-1-adrenoceptor blockade on hormonal and cardiovascular response to insulin-induced hypoglycaemia in insulin-dependent diabetic patients. Scand J Clin Lab Invest 42 (1982) 69-74
37. Byington R.P., Worthy J., Craven T., and Furberg C.D. Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the β-Blocker Heart Attack Trial experience. Am J Cardiol 65 (1990) 1287-1291
38. Vyssoulis G.P., Karpanou E.A., Pitsavos C.E., Skoumas J.N., Paleologos A.A., and Toutouzas P.K. Differentiation of β-blocker effects on serum lipids and apolipoproteins in hypertensive patients with normolipidaemic or dyslipidaemic profiles. Eur Heart J 13 (1992) 1506-1513
39. Fogari R., Zoppi A., Corradi L., Preti P., Mugellini A., and Lusardi P. β-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 33 (1999) 534-539
40. Hylander B., Eliasson K., Nilsson-Ehle P., and Rossner S. Effects of long-term therapy with laβlol on lipoprotein metabolism in patients with mild hypertension. Acta Med Scand 218 (1985) 51-54
41. Ko D.T., Hebert P.R., Coffey C.S., Sedrakyan A., Curtis J.P., and Krumholz H.M. β-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 288 (2002) 351-357
42. Shabsigh R., Perelman M.A., Lockhart D.S., Lue T.F., and Broderick G.A. Health issues of men: prevalence and correlates of erectile dysfunction. J Urol 174 (2005) 662-667
43. Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 65 (2005) 773-786
44. Chen K., Chiou C.F., Plauschinat C.A., Frech F., Harper A., and Dubois R. Patient satisfaction with antihypertensive therapy. J Hum Hypertens 19 (2005) 793-799
45. Veverka A., Nuzum D.S., and Jolly J.L. Nebivolol: a third generation β-adrenergic blocker. Ann Pharmacother 40 (2006) 1353-1360
46. Sule S.S., and Frishman W. Nebivolol. New therapy update. Cardiol Rev 14 (2006) 259-264
47. Van Bortel L.M., Breed J.G., Joosten J., Kragten J.A., Lustermans F.A., and Mooij J.M. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 21 (1993) 856-862
48. Lacourciere Y., Lefebvre J., Poirier L., Archambault F., and Arnott W. Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination. A randomized, double-blind, placebo-controlled, factorial-design trial. Am J Hypertens 7 (1994) 137-145
49. Van Nueten L., Taylor F.R., and Robertson J.I. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Human Hypertens 12 (1998) 135-140
50. Van Nueten L., Schilling A., Vertommen C., Dupont A.G., and Robertson J.I. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J Hum Hypertens 11 (1997) 813-819
51. Mazza A., Gil-Extremera B., Maldonato A., Toutouzas T., and Pessina A.C. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press 11 (2002) 182-188
52. Grassi G., Trevano F.Q., Facchini A., Toutouzas T., Chanu B., and Mancia G. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press 12 suppl 2 (2003) 35-40
53. Czuriga I., Riecansky I., Bodnar J., Fulop T., Kruzsicz E., Edes I., and NEBIS Investigators. Comparison of the new cardioselective β-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther 17 (2003) 257-263
54. Rosei E.A., Rizzoni D., Comini S., Boari G., and Nebivolol-Lisinopril Study Group. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press Suppl 1 (2003) 30-35
55. Van Bortel L.M., Bulpitt C.J., and Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens 18 (2005) 1060-1066
56. Ambrosini E., and Borghi C. Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective β-blockers in the treatment of hypertension. High Blood Press Cardiovasc Prev 12 (2005) 27-35
57. Wang T.J., Gona P., Larson M.G., Tofler G.H., Levy D., Newton-Cheh C., Jacques P.F., Rifai N., Selhub J., Robins S.J., Benjamin E.J., D'Agostino R.B., and Vasan R.S. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355 (2006) 2631-2639
58. Wald N.J., and Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326 (2003) 14-19
59. Bakris G.L., Hart P., and Ritz E. β blockers in the management of chronic kidney disease. Kidney Int 70 (2006) 1905-1913
60. Lindholm L.H., Carlberg B., and Samuelsson O. β blockers in primary hypertension: do age and type of β-blocker matter?. J Hypertens 24 (2006) 2143-2145
61. Ahlquist R.P. Present state of alpha- and β-adrenergic drugs I. The adrenergic receptor. Am Heart J 92 (1976) 661-664
62. Wikstrand J., Warnold I., Olsson G., Tuomilehto J., Elmfeldt D., and Berglund G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259 (1988) 1976-1982
63. Olsson G., Tuomilehto J., Berglund G., Elmfeldt D., Warnold I., Barber H., Eliasson K., Jastrup B., Karatzas N., and Leer J. Primary prevention of sudden cardiovascular death in hypertensive patients. Morality results from the MAPHY Study. Am J Hypertens 4 (1991) 151-158
64. Carlberg B., Samuelsson O., and Lindholm L.H. Atenolol in hypertension: is it a wise choice?. Lancet 364 (2004) 1684-1689
65. Turner R.C., Cull C.A., Frighi V., Holman R.R., and UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281 (1999) 2005-2012
66. Tzemos N., Lim P.O., and MacDonald T.M. Nebivolol reverses endothelial dysfunction in essential hypertension. A randomized, double-blind, crossover study. Circulation 104 (2001) 511-514
67. Mason R.P., Kalinowski L., Jacob R.F., Jacoby A.M., and Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 112 (2005) 3795-3801
68. Peter P., Martin U., Sharmin A., and Dunne F. Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension. J Clin Pharm Ther 31 (2006) 153-159
69. Flather M.D., Shibata M.C., Coats A.J., Van Veldhuisen D.J., Parkhomenko A., Borbola J., Cohen-Solal A., Dumitrascu D., Ferrari R., Lechat P., Soler-Soler J., Tavazzi L., Spinarova L., Toman J., Bohm M., Anker S.D., Thompson S.G., Poole-Wilson P.A., and SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
70. Mason R.P., Kubant R., Jacob R.F., Walter M.F., Boychuk B., and Malinski T. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol 48 (2006) 862-869
71. Cohn J.N., Archibald D.G., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E., Dunkman W.B., Jacobs W., Francis G.S., and Flohr K.H. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study. N Engl J Med 314 (1986) 1547-1552
72. Celik T., Iyisoy A., Kursaklioglu H., Kardesoglu E., Kilic S., Turhan H., Yilmaz M.I., Ozcan O., Yaman H., Isik E., and Fici F. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 24 (2006) 591-596
73. Chobanian A.V., Brecher P., and Chan C. Effects of propranolol on atherogenesis in the cholesterol-fed rabbit. Circ Res 56 (1985) 755-762
74. Grimm Jr. R.H., Grandits G.A., Cutler J.A., Stewart A.L., McDonald R.H., Svendsen K., Prineas R.J., Liebsen P.R., et al., TOMHS Research Group. Relationships of quality of life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study (TOMHS). Arch Intern Med 157 (1997) 638-648